Edition:
United Kingdom

Abeona Therapeutics Receives FDA Fast Track Designation For ABO-101 For Treatment Of Sanfilippo Syndrome Type B (MPS IIIB)


Thursday, 4 Apr 2019 

April 4 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR ABO-101 FOR TREATMENT OF SANFILIPPO SYNDROME TYPE B (MPS IIIB).ABEONA THERAPEUTICS INC - ABEONA IS ENROLLING ELIGIBLE PATIENTS WITH MPS IIIB AT SITES IN U.S. AND SPAIN. 

Company Quote

7.02
-0.4 -5.39%
7:34pm BST